LUMAKRAS — AMGEN INC, approved 2025-01-16 (NDA214665).
2,535 reports across the top reactions. These are spontaneously reported events from the FDA Adverse Event Reporting System — they reflect reporting volume, not incidence or frequency, and a report does not mean the drug caused the event.